경구 경점막 약물 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)
Global Oral Transmucosal Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033
상품코드:1820638
리서치사:Value Market Research
발행일:2025년 07월
페이지 정보:영문 147 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 경구 경점막 약물 시장은 2025-2033년 주목할 만한 CAGR 6.98%로 성장할 것으로 예측됩니다. 시장 규모는 2033년까지 754억 8,000만 달러로 급증하며 2024년에 기록한 411억 2,000만 달러에서 크게 증가할 것으로 예측됩니다.
세계의 경구 경점막 약물 시장은 비침습적이고 즉각적인 약물 전달 시스템에 대한 수요가 증가함에 따라 성장할 전망입니다. 뺨과 설하를 포함한 경구 경점막 경로는 초기 통과 대사를 우회하고 환자의 컴플라이언스를 향상시키는 등의 이점을 제공합니다. 향후 개발에서는 생체이용률과 치료 효과를 높이기 위한 신규 제제, 점착 기술, 나노 캐리어 시스템이 주목됩니다.
게다가 만성 통증, 신경 질환, 심혈관 질환의 유병률 상승으로 용도 분야가 확대되고 있습니다. 약물 전달 장치 및 맞춤형 의료의 진보가 시장 성장을 더욱 강화하고 있습니다. 혁신적인 전달 시스템을 지원하는 규제 체제가 상업화를 촉진하고 있습니다. 환자 중심의 치료가 주목되고 있는 가운데, 경구 경점막 약물 시장은 앞으로도 혁신을 계속해, 효과적이고 편리하고 안전한 치료의 선택지를 제공해 나갈 것입니다.
목차
제1장 서문
제2장 주요 요약
시장의 하이라이트
세계 시장 현황
제3장 경구 경점막 약물 : 산업 분석
서문 : 시장 역학
시장 성장 촉진요인
시장 성장 억제요인
시장 기회
업계 동향
Porter's Five Forces 분석
시장 매력 분석
제4장 밸류체인 분석
밸류체인 분석
원재료 분석
원재료 리스트
원재료 제조업체 리스트
주요 원재료의 가격 동향
잠재적 구매자 목록
마케팅 채널
직접 마케팅
간접 마케팅
마케팅 채널 발전 동향
제5장 세계의 경구 경점막 약물 시장 분석 : 제품 유형별
개요 : 제품 유형별
과거 및 예측 데이터 분석 : 제품 유형별
태블릿
필름
액체 및 스프레이
기타 제품 유형
제6장 세계의 경구 경점막 약물 시장 분석 : 투여 경로별
개요 : 투여 경로별
과거 및 예측 데이터 분석 : 투여 경로별
설하 점막
뺨 점막
기타 투여 경로
제7장 세계의 경구 경점막 약물 시장 분석 : 적응증별
개요 : 적응증별
과거 및 예측 데이터 분석 : 적응증별
오피오이드 의존증
메스꺼움 및 구토
발기부전
신경질환
기타 적응증
제8장 세계의 경구 경점막 약물 시장 분석 : 유통 채널별
개요 : 유통 채널별
과거 및 예측 데이터 분석 : 유통 채널별
병원 약국
소매 약국
온라인 약국
제9장 세계의 경구 경점막 약물 시장 분석 : 지역별
지역별 전망
서문
북미의 매출 분석
개요, 분석 및 예측
북미 : 부문별
북미 국가별
미국
캐나다
멕시코
유럽의 매출 분석
개요, 분석 및 예측
유럽 : 부문별
유럽 국가별
영국
프랑스
독일
이탈리아
러시아
기타 유럽
아시아태평양의 매출 분석
개요, 분석 및 예측
아시아태평양 : 부문별
아시아태평양 국가별
중국
인도
일본
한국
호주
동남아시아
기타 아시아태평양
라틴아메리카의 매출 분석
개요, 분석 및 예측
라틴아메리카 : 부문별
라틴아메리카 국가별
브라질
아르헨티나
페루
칠레
기타 라틴아메리카
중동 및 아프리카의 매출 분석
개요, 분석 및 예측
중동 및 아프리카 : 부문별
중동 및 아프리카 국가별 일람
사우디아라비아
아랍에미리트(UAE)
이스라엘
남아프리카
기타 중동 및 아프리카
제10장 경구 경점막 약물 기업 경쟁 구도
경구 경점막 약물 시장의 경쟁
제휴, 협력 및 합의
합병 및 인수
신제품 출시
기타 개발
제11장 기업 프로파일
주요 기업의 시장 점유율 분석
시장 집중도
Esteive Therapeutics Inc.
CLPharm Co. Ltd.
Cure Pharmaceutical
IntelGenx Technologies Corp
Jazz Pharmaceuticals Plc
NAL Pharma
Novartis AG
Pfizer Inc.
Teva Pharmaceutical Industries Limited
ZIM Laboratories Limited
AJY
영문 목차
영문목차
The global Oral Transmucosal Drugs market is forecasted to grow at a noteworthy CAGR of 6.98% between 2025 and 2033. By 2033, market size is expected to surge to USD 75.48 Billion, a substantial rise from the USD 41.12 Billion recorded in 2024.
The global oral transmucosal drugs market is poised for growth driven by increasing demand for non-invasive, rapid-onset drug delivery systems. Oral transmucosal routes, including buccal and sublingual, offer advantages such as bypassing first-pass metabolism and improving patient compliance. Future developments will focus on novel formulations, mucoadhesive technologies, and nanocarrier systems to enhance bioavailability and therapeutic efficacy.
Moreover, rising prevalence of chronic pain, neurological disorders, and cardiovascular diseases is expanding application areas. Advances in drug delivery devices and personalized medicine are further propelling market growth. Regulatory frameworks supporting innovative delivery systems are facilitating commercialization. As patient-centric therapies gain prominence, the oral transmucosal drugs market will continue to innovate, delivering effective, convenient, and safe treatment options.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
LIST OF SEGMENTS COVERED
This section of the Oral Transmucosal Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
3.7.1 Market Attractiveness Analysis By Product Type
3.7.2 Market Attractiveness Analysis By Route Of Administration
3.7.3 Market Attractiveness Analysis By Indication
3.7.4 Market Attractiveness Analysis By Distribution Channel
3.7.5 Market Attractiveness Analysis By Regions
4. VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1 List of Raw Materials
4.2.2 Raw Material Manufactures List
4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1 Direct Marketing
4.4.2 Indirect Marketing
4.4.3 Marketing Channel Development Trend
5. GLOBAL ORAL TRANSMUCOSAL DRUGS MARKET ANALYSIS BY PRODUCT TYPE
5.1. Overview By Product Type
5.2. Historical and Forecast Data Analysis By Product Type
5.3. Tablets Historic and Forecast Sales By Regions
5.4. Films Historic and Forecast Sales By Regions
5.5. Liquid & Spray Historic and Forecast Sales By Regions
5.6. Other Product Types Historic and Forecast Sales By Regions
6. GLOBAL ORAL TRANSMUCOSAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.1. Overview By Route Of Administration
6.2. Historical and Forecast Data Analysis By Route Of Administration
6.3. Sublingual Mucosa Historic and Forecast Sales By Regions
6.4. Buccal Mucosa Historic and Forecast Sales By Regions
6.5. Other Routes Of Administration Historic and Forecast Sales By Regions
7. GLOBAL ORAL TRANSMUCOSAL DRUGS MARKET ANALYSIS BY INDICATION
7.1. Overview By Indication
7.2. Historical and Forecast Data Analysis By Indication
7.3. Opioid Dependence Historic and Forecast Sales By Regions
7.4. Nausea And Vomiting Historic and Forecast Sales By Regions
7.5. Erectile Dysfunction Historic and Forecast Sales By Regions
7.6. Neurological Disorders Historic and Forecast Sales By Regions
7.7. Other Indications Historic and Forecast Sales By Regions
8. GLOBAL ORAL TRANSMUCOSAL DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL
8.1. Overview By Distribution Channel
8.2. Historical and Forecast Data Analysis By Distribution Channel
8.3. Hospital Pharmacies Historic and Forecast Sales By Regions
8.4. Retail Pharmacies Historic and Forecast Sales By Regions
8.5. Online Pharmacies Historic and Forecast Sales By Regions
9. GLOBAL ORAL TRANSMUCOSAL DRUGS MARKET ANALYSIS BY GEOGRAPHY
9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
9.3.1 Overview, Historic and Forecast Data Sales Analysis
9.3.2 North America By Segment Sales Analysis
9.3.3 North America By Country Sales Analysis
9.3.4 United States Sales Analysis
9.3.5 Canada Sales Analysis
9.3.6 Mexico Sales Analysis
9.4. Europe Sales Analysis
9.4.1 Overview, Historic and Forecast Data Sales Analysis
9.4.2 Europe By Segment Sales Analysis
9.4.3 Europe By Country Sales Analysis
9.4.4 United Kingdom Sales Analysis
9.4.5 France Sales Analysis
9.4.6 Germany Sales Analysis
9.4.7 Italy Sales Analysis
9.4.8 Russia Sales Analysis
9.4.9 Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
9.5.1 Overview, Historic and Forecast Data Sales Analysis
9.5.2 Asia Pacific By Segment Sales Analysis
9.5.3 Asia Pacific By Country Sales Analysis
9.5.4 China Sales Analysis
9.5.5 India Sales Analysis
9.5.6 Japan Sales Analysis
9.5.7 South Korea Sales Analysis
9.5.8 Australia Sales Analysis
9.5.9 South East Asia Sales Analysis
9.5.10 Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
9.6.1 Overview, Historic and Forecast Data Sales Analysis
9.6.2 Latin America By Segment Sales Analysis
9.6.3 Latin America By Country Sales Analysis
9.6.4 Brazil Sales Analysis
9.6.5 Argentina Sales Analysis
9.6.6 Peru Sales Analysis
9.6.7 Chile Sales Analysis
9.6.8 Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
9.7.1 Overview, Historic and Forecast Data Sales Analysis
9.7.2 Middle East & Africa By Segment Sales Analysis
9.7.3 Middle East & Africa By Country Sales Analysis
9.7.4 Saudi Arabia Sales Analysis
9.7.5 UAE Sales Analysis
9.7.6 Israel Sales Analysis
9.7.7 South Africa Sales Analysis
9.7.8 Rest Of Middle East And Africa Sales Analysis
10. COMPETITIVE LANDSCAPE OF THE ORAL TRANSMUCOSAL DRUGS COMPANIES
10.1. Oral Transmucosal Drugs Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments
11. COMPANY PROFILES OF ORAL TRANSMUCOSAL DRUGS INDUSTRY
11.1. Top Companies Market Share Analysis
11.2. Market Concentration Rate
11.3. Aquestive Therapeutics Inc.
11.3.1 Company Overview
11.3.2 Company Revenue
11.3.3 Products
11.3.4 Recent Developments
11.4. C.L.Pharm Co. Ltd.
11.4.1 Company Overview
11.4.2 Company Revenue
11.4.3 Products
11.4.4 Recent Developments
11.5. Cure Pharmaceutical
11.5.1 Company Overview
11.5.2 Company Revenue
11.5.3 Products
11.5.4 Recent Developments
11.6. IntelGenx Technologies Corp
11.6.1 Company Overview
11.6.2 Company Revenue
11.6.3 Products
11.6.4 Recent Developments
11.7. Jazz Pharmaceuticals Plc
11.7.1 Company Overview
11.7.2 Company Revenue
11.7.3 Products
11.7.4 Recent Developments
11.8. NAL Pharma
11.8.1 Company Overview
11.8.2 Company Revenue
11.8.3 Products
11.8.4 Recent Developments
11.9. Novartis AG
11.9.1 Company Overview
11.9.2 Company Revenue
11.9.3 Products
11.9.4 Recent Developments
11.10. Pfizer Inc.
11.10.1 Company Overview
11.10.2 Company Revenue
11.10.3 Products
11.10.4 Recent Developments
11.11. Teva Pharmaceutical Industries Limited
11.11.1 Company Overview
11.11.2 Company Revenue
11.11.3 Products
11.11.4 Recent Developments
11.12. ZIM Laboratories Limited
11.12.1 Company Overview
11.12.2 Company Revenue
11.12.3 Products
11.12.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies
